Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 162

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

NEUTRALIZING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIBODY INHIBITS FURTHER GROWTH OF ESTABLISHED PROSTATE CANCER AND METASTASES IN A PRE-CLINICAL MODEL

MELNYK, OSTAP, ZIMMERMAN, MICHAEL, KIM, K. JIN, SHUMAN, MARC · 1999 · Journal of Urology

Abstract

PURPOSE: The formation of new blood vessels from the pre-existing vasculature is necessary for support of primary tumor growth and appears coincident with the development of metastasis. In previous studies, inhibition of vascular endothelial growth factor (VEGF), a potent angiogenic factor and mediator of vascular permeability, inhibited tumor neovascularization with consequent inhibition of both primary tumor growth and micrometastases when administered at the time of tumor inoculation. In the present study, we examined the effect of inhibiting VEGF on primary tumor growth and metastases in an in vivo model of established metastatic prostate cancer. MATERIALS AND METHODS: The human prostate cancer cell line DU-145 was found to secrete VEGF. DU-145.luciferase, a subclone stably transfected with an expression vector encoding the luciferase gene, injected subcutaneously, consistently formed tumors in C.B.-17 scid/scid mice. After 6 weeks, assay of whole lung lysates showed significant luciferase activity, consistent with the presence of micrometastasis. RESULTS: Twice weekly treatment of the animals with a monoclonal anti-VEGF neutralizing antibody, A4.6.1, not only suppressed primary tumor growth, but inhibited metastatic dissemination to the lung. When treatment was delayed until the primary tumors were well-established, further growth was still inhibited, as was the progression of metastatic disease. CONCLUSION: Inhibition of tumor-secreted VEGF by a neutralizing antibody is sufficient to significantly impair prostate tumor growth and its subsequent metastasis in an in vivo model of established advanced prostate cancer. These data suggest a critical role for VEGF in initiation and maintenance of tumor angiogenesis in prostate cancer. Inhibition of VEGF in patients with VEGF-secreting prostate cancers may prove an effective approach for inhibiting disease progression even after micro-metastatic dissemination has occurred.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0022-5347(01)61829-9

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 162

Metadata

Authors
MELNYK, O., ZIMMERMAN, M., KIM, K. J., & SHUMAN, M.
Venue
Journal of Urology
Published
1999-03
Volume
161
Issue
3
Pages
960-963
ISSN
  • 0022-5347 (ISSN-L)
  • 1527-3792
OpenAlex
W2054822632
Cited by
162
References
2
FWCI
5.55
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NEUTRALIZING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIBODY INHIBITS FURTHER GROWTH OF ESTABLISHED PROSTATE CANCER AND METASTASES IN A PRE-CLINICAL MODEL. https://app.cochat.ai/papers/10.1016/s0022-5347(01)61829-9
The paper
MELNYK, O., ZIMMERMAN, M., KIM, K. J., & SHUMAN, M. (1999). NEUTRALIZING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIBODY INHIBITS FURTHER GROWTH OF ESTABLISHED PROSTATE CANCER AND METASTASES IN A PRE-CLINICAL MODEL. Journal of Urology. https://doi.org/10.1016/s0022-5347(01)61829-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.